@article {Palmu2020.02.08.20021022, author = {Joonatan Palmu and Jeramie D. Watrous and Kysha Mercader and Aki S. Havulinna and Kim A. Lagerborg and Aaro Salosensaari and Mike Inouye and Martin G. Larson and Jian Rong and Ramachandran S. Vasan and Leo Lahti and Allen Andres and Susan Cheng and Pekka Jousilahti and Veikko Salomaa and Mohit Jain and Teemu J. Niiranen}, title = {Eicosanoid Inflammatory Mediators Are Robustly Associated with Blood Pressure in the General Population}, elocation-id = {2020.02.08.20021022}, year = {2020}, doi = {10.1101/2020.02.08.20021022}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Epidemiological and animal studies have associated systemic inflammation with blood pressure (BP). However, the mechanistic factors linking inflammation and BP remain unknown. Fatty acid derived eicosanoids serve as mediators of inflammation and have been suggested to also regulate renal vascular tone, peripheral resistance, renin-angiotensin system, and endothelial function. We therefore hypothesize that specific pro- and anti-inflammatory eicosanoids are linked with BP. We studied a population sample of 8099 FINRISK 2002 participants randomly drawn from the Finnish population register (53\% women, mean age 48{\textpm}13 years) and, for external validation, a sample of 2859 Framingham Heart Study (FHS) Offspring study participants (55\% women, mean age 66{\textpm}9 years). Using non-targeted liquid chromatography-mass spectrometry, we profiled 545 distinct high-quality eicosanoids and related oxylipin mediators in plasma. Adjusting for conventional hypertension risk factors, we observed 187 (34\%) metabolites that were significantly associated with systolic BP (P \< Bonferroni-corrected threshold of 0.05/545). We used forward selection linear regression modeling in FINRISK to define a general formula for individual eicosanoid risk score. Individuals of the top risk score quartile in FINRISK had a 9.0 mmHg (95\% CI 8.0-10.1) higher systolic BP compared with individuals in the lowest quartile in fully adjusted models. Observed metabolite associations were consistent across FINRISK and FHS. In conclusion, plasma eicosanoids demonstrate strong associations with BP in the general population. As eicosanoid compounds affect numerous physiological processes that are central to BP regulation, they may offer new insights regarding pathogenesis of hypertension, as well as serve as potential targets for therapeutic intervention.Competing Interest StatementVS has received honoraria from Novo Nordisk and Sanofi for consultations and travel support from Novo Nordisk. He also has ongoing research collaboration with Bayer Ltd. (All unrelated to the present study)Funding StatementThis work was supported by the Emil Aaltonen Foundation (TN), the Paavo Nurmi Foundation (TN), the Finnish Medical Foundation (TN), the Finnish Foundation for Cardiovascular Research (VS), the Academy of Finland (grant n:o 321351 to TN; 295741, 307127 to LL, 321356 to ASH), Ellison Foundation (SC) and the National Heart, Lung and Blood Institute{\textquoteright}s Framingham Heart Study (contracts N01HC25195, HHSN268201500001I, and 75N92019D00031), and the following National Institutes of Health grants: R01HL093328 (RSV), R01HL107385 (RSV), R01HL126136 (RSV), R00HL107642 (SC), R01HL131532 (SC), R01HL134168 (SC, MJ), R01HL143227 (SC, MJ), R01ES027595 (MJ, SC), and K01DK116917 (JDW). Dr. Vasan is supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available at THL Biobank (https://thl.fi/en/web/thl-biobank) except for LQ/MS data that is being prepared for publication.}, URL = {https://www.medrxiv.org/content/early/2020/03/30/2020.02.08.20021022}, eprint = {https://www.medrxiv.org/content/early/2020/03/30/2020.02.08.20021022.full.pdf}, journal = {medRxiv} }